Search results for #OVCA
Thank you to @ShannonWestin of @MDAndersonNews for speaking with us on the WEE1 pathway in ovarian and uterine carcinoma. Check out OncLive.com for more #gyncsm #ovca treatment updates from experts like Dr Westin! onclive.com/clinical/gynec…
Avutometinib plus defactinib elicited high response rates in heavily pretreated patients with recurrent low-grade serous ovarian cancer regardless of the number of prior lines of therapy received. @BanerjeeSusana @royalmarsdenNHS @SGO_org #SGOMtg #ovca onclive.com/view/avutometi…
ctDNA may serve as a tool to aid clinician decision making regarding whether to proceed with or discontinue PARP inhibitor maintenance therapy for patients with recurrent epithelial ovarian cancer. #ovca #oncology onclive.com/view/ctdna-off…
A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL. #ovca #gynsm #oncology onclive.com/view/brexu-cel…
The FDA granted regular approval to mirvetuximab soravtansine for pretreated patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. @US_FDA #ovca #gynsm #oncology onclive.com/view/fda-appro…
Ixabepilone plus bevacizumab produced a survival advantage and high response rates vs ixabepilone alone in platinum-resistant ovarian cancer. #ovca #oncology onclive.com/view/ixabepilo…
NXP800, a novel GCN2 kinase activator, is under further evaluation as a treatment for patients with platinum-resistant, ARID1A-mutated ovarian cancer, in the phase 1b ENGOT-GYN5/NCRI/NXP800-101 trial . @BanerjeeSusana @royalmarsdenNHS #SGOMtg #ovca onclive.com/view/nxp800-un…
The FDA has granted regular approval to mirvetuximab soravtansine-gynx for select patients with pretreated FRα-positive, platinum-resistant ovarian cancer. @US_FDA #ovca #gynsm #oncology onclive.com/view/fda-appro…
Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer. @BanerjeeSusana @royalmarsdenNHS @SGO_org #SGOMtg #ovca onclive.com/view/avutometi…
According to data from a phase 1 trial, CRX100 plus a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in patients with recurrent, platinum-resistant ovarian cancer. #SGOMtg #ovca #oncology onclive.com/view/crx100-el…
According to data from the phase 1/2 PYNNACLE study, rezatapopt induced responses with acceptable toxicity in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations. @AliSchram #SGOMtg #ovca #oncology onclive.com/view/rezatapop…
Ask me about the falloposcope #SIR2024 #infertility #OvCa #OCT #shennanahooligans @BradWoodMD @SIRRFS
ICYMI: Watch Gottfried E. Konecny, MD, @UCLAJCCC, discuss the @US_FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer. #ovca #oncology onclive.com/view/dr-konecn…
From key sessions at the 2024 SGO Annual Meeting to updates in the field, gynecologic oncology experts share their key takeaways from the meeting. @SGO_org #SGOMtg #ovca #gynsm onclive.com/view/experts-s…
@marklewismd Others, including my self, speculated it was ovarian cancer.Many women learn after surgery that they have #OVCA. Some of us are very open and others are totally private about our cancers and I respect her choice.
Mirvetuximab soravtansine improved health-related quality of life in patients with FRα-positive, platinum-resistant ovarian cancer. @SGO_org #SGOMtg #ovca #oncology onclive.com/view/mirvetuxi…
ctDNA may aid clinicians in determining whether to proceed with or discontinue PARP inhibitor maintenance therapy for patients with recurrent epithelial ovarian cancer. #ovca #oncology onclive.com/view/ctdna-off…